287 related articles for article (PubMed ID: 19383830)
21. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
22. Differential display in primary and metastatic medullary thyroid carcinoma.
Musholt TJ; Goodfellow PJ; Scheumann GF; Pichlmayr R; Wells SA; Moley JF
J Surg Res; 1997 Apr; 69(1):94-100. PubMed ID: 9202653
[TBL] [Abstract][Full Text] [Related]
23. Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities.
Machens A; Lorenz K; Dralle H
J Intern Med; 2009 Jul; 266(1):114-25. PubMed ID: 19522830
[TBL] [Abstract][Full Text] [Related]
24. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.
Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS
J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma.
Cebrian A; Lesueur F; Martin S; Leyland J; Ahmed S; Luccarini C; Smith PL; Luben R; Whittaker J; Pharoah PD; Dunning AM; Ponder BA
J Clin Endocrinol Metab; 2005 Nov; 90(11):6268-74. PubMed ID: 16091499
[TBL] [Abstract][Full Text] [Related]
26. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome.
Abu-Amero KK; Alzahrani AS; Zou M; Shi Y
Oncogene; 2006 Feb; 25(5):677-84. PubMed ID: 16205644
[TBL] [Abstract][Full Text] [Related]
27. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.
Koga K; Hattori Y; Komori M; Narishima R; Yamasaki M; Hakoshima M; Fukui T; Maitani Y
Cancer Sci; 2010 Apr; 101(4):941-7. PubMed ID: 20704575
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and therapeutic aspects in medullary thyroid carcinoma.
Safioleas M; Stamatakos M; Karampali E; Rompoti N; Mouzopoulos G; Lygidakis N
Chirurgia (Bucur); 2006; 101(2):121-6. PubMed ID: 16752676
[TBL] [Abstract][Full Text] [Related]
29. Medullary thyroid carcinoma: surgical treatment advances.
Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
[TBL] [Abstract][Full Text] [Related]
30. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma.
Messina M; Robinson BG
Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):290-301. PubMed ID: 17315037
[TBL] [Abstract][Full Text] [Related]
31. New directions in the treatment of thyroid cancer.
You YN; Lakhani V; Wells SA
J Am Coll Surg; 2007 Oct; 205(4 Suppl):S45-8. PubMed ID: 17916518
[No Abstract] [Full Text] [Related]
32. [Medullary thyroid carcinoma and some of its particularities].
Sidibé el H
Sante; 2007; 17(1):51-5. PubMed ID: 17897902
[TBL] [Abstract][Full Text] [Related]
33. [RET and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
[TBL] [Abstract][Full Text] [Related]
34. Medical management of metastatic medullary thyroid cancer.
Maxwell JE; Sherman SK; O'Dorisio TM; Howe JR
Cancer; 2014 Nov; 120(21):3287-301. PubMed ID: 24942936
[TBL] [Abstract][Full Text] [Related]
35. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.
Milos IN; Frank-Raue K; Wohllk N; Maia AL; Pusiol E; Patocs A; Robledo M; Biarnes J; Barontini M; Links TP; de Groot JW; Dvorakova S; Peczkowska M; Rybicki LA; Sullivan M; Raue F; Zosin I; Eng C; Neumann HP
Endocr Relat Cancer; 2008 Dec; 15(4):1035-41. PubMed ID: 18794325
[TBL] [Abstract][Full Text] [Related]
36. A dog pedigree with familial medullary thyroid cancer.
Lee JJ; Larsson C; Lui WO; Höög A; Von Euler H
Int J Oncol; 2006 Nov; 29(5):1173-82. PubMed ID: 17016649
[TBL] [Abstract][Full Text] [Related]
37. Medullary thyroid cancer: a promising model for targeted therapy.
Torino F; Paragliola RM; Barnabei A; Corsello SM
Curr Mol Med; 2010 Oct; 10(7):608-25. PubMed ID: 20712590
[TBL] [Abstract][Full Text] [Related]
38. The RET functional variant c 587T>C is not associated with susceptibility to sporadic medullary thyroid cancer.
Fernández RM; Sánchez-Mejías A; Navarro E; López-Alonso M; Antiñolo G; Borrego S
Thyroid; 2009 Sep; 19(9):1017-8. PubMed ID: 19678735
[No Abstract] [Full Text] [Related]
39. Medullary thyroid cancer: early detection and novel treatments.
Roman S; Mehta P; Sosa JA
Curr Opin Oncol; 2009 Jan; 21(1):5-10. PubMed ID: 19125012
[TBL] [Abstract][Full Text] [Related]
40. Current management of medullary thyroid cancer.
Sippel RS; Kunnimalaiyaan M; Chen H
Oncologist; 2008 May; 13(5):539-47. PubMed ID: 18515739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
